Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Liabilities and Shareholders Equity (2024 - 2025)

Historic Liabilities and Shareholders Equity for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $133.7 million.

  • Xilio Therapeutics' Liabilities and Shareholders Equity rose 7907.52% to $133.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $442.3 million, marking a year-over-year change of. This contributed to the annual value of $71.1 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Xilio Therapeutics' Liabilities and Shareholders Equity is $133.7 million, which was up 7907.52% from $133.8 million recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' Liabilities and Shareholders Equity ranged from a high of $133.8 million in Q2 2025 and a low of $71.1 million during Q4 2024